AT280499B - Verfahren zur Herstellung neuer 4,6-Dichlor-Δ<4,6>-steroide der Pregnan- und Androstanreihe - Google Patents

Verfahren zur Herstellung neuer 4,6-Dichlor-Δ<4,6>-steroide der Pregnan- und Androstanreihe

Info

Publication number
AT280499B
AT280499B AT516368A AT516368A AT280499B AT 280499 B AT280499 B AT 280499B AT 516368 A AT516368 A AT 516368A AT 516368 A AT516368 A AT 516368A AT 280499 B AT280499 B AT 280499B
Authority
AT
Austria
Prior art keywords
pregnane
steroids
dichloro
new
production
Prior art date
Application number
AT516368A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of AT280499B publication Critical patent/AT280499B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT516368A 1967-06-09 1968-05-29 Verfahren zur Herstellung neuer 4,6-Dichlor-Δ<4,6>-steroide der Pregnan- und Androstanreihe AT280499B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE1967SC040852 DE1643027B2 (de) 1967-06-09 1967-06-09 4,6-dichlor-delta hoch 4,6- steroide der pregnanreihe

Publications (1)

Publication Number Publication Date
AT280499B true AT280499B (de) 1970-04-10

Family

ID=7435899

Family Applications (1)

Application Number Title Priority Date Filing Date
AT516368A AT280499B (de) 1967-06-09 1968-05-29 Verfahren zur Herstellung neuer 4,6-Dichlor-Δ<4,6>-steroide der Pregnan- und Androstanreihe

Country Status (17)

Country Link
US (1) US3789087A (de)
AT (1) AT280499B (de)
BE (1) BE716258A (de)
BR (1) BR6899582D0 (de)
CH (1) CH560230A5 (de)
CS (1) CS163723B2 (de)
DE (1) DE1643027B2 (de)
DK (2) DK124610B (de)
ES (1) ES354795A1 (de)
FI (1) FI45176C (de)
FR (2) FR1588812A (de)
GB (1) GB1240339A (de)
NL (1) NL161768C (de)
NO (1) NO129522B (de)
PL (1) PL73566B1 (de)
SE (1) SE341396B (de)
YU (1) YU33977B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0792152B1 (de) 1994-11-22 2004-04-14 Balance Pharmaceuticals, Inc. Verfahren zur empfängnisverhütung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB838773A (en) * 1955-07-20 1960-06-22 Farmaceutici Italia 4-substituted steroid compounds and preparation thereof
US3452058A (en) * 1958-11-13 1969-06-24 Syntex Corp 6-substituted-6-dehydro androstanes and pregnanes
GB1050218A (de) * 1964-10-13
DE1593516C3 (de) * 1966-08-25 1975-05-15 Schering Ag, 1000 Berlin Und 4619 Bergkamen 4-Halogen-1,2 alpha; 6,7 betabismethylen-delta hoch 4-3-ketosteroide, Verfahren zu ihrer Herstellung sowie diese Steroide enthaltende Mittel
US3707537A (en) * 1969-01-08 1972-12-26 Hoffmann La Roche 4-chloro-4,6-diene-6-halo or lower alkyl steroids

Also Published As

Publication number Publication date
NL161768B (nl) 1979-10-15
FR1588812A (de) 1970-03-16
BR6899582D0 (pt) 1973-05-10
CH560230A5 (de) 1975-03-27
YU127868A (en) 1978-02-28
DE1643027B2 (de) 1977-12-08
NL6808107A (de) 1968-12-10
DE1643027C3 (de) 1978-08-17
FR8342M (de) 1970-12-21
BE716258A (de) 1968-12-09
NL161768C (nl) 1980-03-17
DE1643027A1 (de) 1971-04-15
ES354795A1 (es) 1969-11-01
CS163723B2 (de) 1975-11-07
YU33977B (en) 1978-09-08
NO129522B (de) 1974-04-22
SE341396B (de) 1971-12-27
US3789087A (en) 1974-01-29
FI45176C (fi) 1972-04-10
DK124610B (da) 1972-11-06
DK128189B (da) 1974-03-18
PL73566B1 (de) 1974-10-31
GB1240339A (en) 1971-07-21
FI45176B (de) 1971-12-31

Similar Documents

Publication Publication Date Title
AT279815B (de) Verfahren zur Herstellung neuer Gona-1,3,5(10)-triene
AT265539B (de) Verfahren zur Herstellung neuer Steroid- [17α,16α-d]-oxazoline
AT279636B (de) Verfahren zur Herstellung neuer Benzomorphanderivate
CH517723A (de) Verfahren zur Herstellung von Steroidderivaten
AT290741B (de) Verfahren zur Herstellung von neuen Pregnan-Derivaten
AT280499B (de) Verfahren zur Herstellung neuer 4,6-Dichlor-Δ&lt;4,6&gt;-steroide der Pregnan- und Androstanreihe
CH540896A (de) Verfahren zur Herstellung von 15,16B-Methylensteroiden
AT281316B (de) Verfahren zur Herstellung von neuen 2,2-Dimethylsteroiden
CH500972A (de) Verfahren zur Herstellung neuer Spiro-azatetramethylen-Derivate
AT287933B (de) Verfahren zur Herstellung von neuen 17α-Änthinylsteroiden
AT280493B (de) Verfahren zur Herstellung neuer Gona-4,9,11-triene
CH473807A (de) Verfahren zur Herstellung neuer 4-Hydroxy-chinoline
AT285835B (de) Verfahren zur Herstellung C17-oxygenierten Steroiden der Androstanreihe
AT244510B (de) Verfahren zur Herstellung neuer Colchicinderivate
CH491101A (de) Verfahren zur Herstellung neuer 3-Oxo-A,19-bis-nor-B-homo-steroid-4(10)-ene
AT257853B (de) Verfahren zur Herstellung neuer Steroidester der Pregnanreihe
AT301041B (de) Verfahren zur Herstellung von neuen 18-Methylensteroiden
CH505807A (de) Verfahren zur Herstellung neuer 8,14-seco-B-Homogonane
AT266344B (de) Verfahren zur Herstellung neuer Diaminosteroide
AT253136B (de) Verfahren zur Herstellung von 3-Keto-Δ&lt;4,6&gt;-steroiden der Androstan- und Pregnanreihe
CH487880A (de) Verfahren zur Herstellung neuer 1(10),5-Oxo 5,10-Secosteroide der Androstan- und Pregnanreihe oder deren 19-nor-Derivate
CH526522A (de) Verfahren zur Herstellung von Steroidderivaten
CH518919A (de) Verfahren zur Herstellung von 9(11)-Dehydrosteroiden der Androstan- und Pregnanreihe
AT280495B (de) Verfahren zur Herstellung von neuen 1,2α-Methylensteroiden
AT270100B (de) Verfahren zur Herstellung neuer 1,2α-Methylensteroide

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee